Objectives: To investigate the potential role of Yersinia enterocolitica in patients with chronic fatigue syndrome (CFS).
Methods: An immunoblot technique was used to detect antibodies to various Yersinia outer membrane proteins (YOPs) in serum samples from 88 patients with CFS and 77 healthy neighbourhood controls, matched for gender and age.
Results: The prevalence of IgG and IgA antibodies to various Yersinia outer membrane proteins (YOPs) did not differ between patients with CFS and healthy controls. Twenty-four patients (27%) and nineteen controls (25%) had IgG antibodies to one or more YOPs. Four patients and two controls had both serum IgG and IgA antibodies to at least two different YOPs, compatible with a recent or persistent infection. Although all patients with positive IgG and IgA reactions to two or more YOPs had symptoms that could point to persistent Yersinia infection, these symptoms were also found frequently in patients without antibodies to YOPs.
Conclusions: We conclude that Y. enterocolitica is unlikely to play a major role in the aetiology of CFS.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0163-4453(98)94099-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.
Arch Dermatol Res
January 2025
Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA.
Background: Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.
View Article and Find Full Text PDFArciform Erythematous Plaques With Hypopyon Sign.
Int J Dermatol
January 2025
Dermatology Department, Hospital Universitario 'Dr. José Eleuterio González', Universidad Autónoma de Nuevo León, Monterrey, Mexico.
Antibody responses in omicron BF.7-infected patients vaccinated with inactivated SARS-CoV-2.
Virology
January 2025
Xinxiang Medical College, Xinxiang, Henan, 453000, China. Electronic address:
Objective: Our study aimed to investigate antibody responses in omicron BF.7-infected patients after being vaccinated with inactivated SARS-CoV-2.
Methods: Blood serum samples were collected every 2-7 d, 1 w before infection, during the acute infection period and recovery period, and every month after recovery to detect IgG, IgM, IgA, neutralizing antibodies, and neutralizing antibodies against different omicrons in the acute phase.
Mucosal immunity elicited by a human-Fcγ receptor-I targeted intranasal vaccine platform enhances resistance against nasopharyngeal colonization of Streptococcus pneumoniae and induces broadly protective immunity against respiratory pathogens.
Vaccine
January 2025
Department of Immunology and Microbial Disease, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, United States.
The development of safe and effective mucosal vaccines are hampered by safety concerns associated with adjuvants or live attenuated microbes. We previously demonstrated that targeting antigens to the human-Fc-gamma-receptor-I (hFcγRI) eliminates the need for adjuvants, thereby mitigating safety concerns associated with the mucosal delivery of adjuvant formulated vaccines. Here we evaluated the role of the route of immunization in the mucosal immunity elicited by the hFcγRI-targeted vaccine approach.
View Article and Find Full Text PDFRapid and comprehensive detection of viral antibodies and nucleic acids via an acoustofluidic integrated molecular diagnostics chip: AIMDx.
Sci Adv
January 2025
Thomas Lord Department of Mechanical Engineering and Materials, Duke University, Durham, NC 27708, USA.
Precise and rapid disease detection is critical for controlling infectious diseases like COVID-19. Current technologies struggle to simultaneously identify viral RNAs and host immune antibodies due to limited integration of sample preparation and detection. Here, we present acoustofluidic integrated molecular diagnostics (AIMDx) on a chip, a platform enabling high-speed, sensitive detection of viral immunoglobulins [immunoglobulin A (IgA), IgG, and IgM] and nucleic acids.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!